EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017–2019

Ana C Gales, Gregory Stone, Daniel F Sahm, Mark G Wise, Eric Utt iD

Journal of Antimicrobial Chemotherapy · 05.07.2023 · 78 (7) · 1606-1615

DOI: 10.1093/jac/dkad127 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 10.05.2023. Verfasst von Ana C Gales und 4 weiteren Autor:innen. Beteiligte Einrichtung: Universidade Federal de São Paulo - UNIFESP, Division of Infectious Diseases, Department of Internal Medicine, Escola Paulista de Medicina - EPM, São…. Hauptthemen laut MEDLINE: Ceftazidime, Pseudomonas aeruginosa. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

To assess the global and regional distribution of ESBLs in Enterobacterales and carbapenemases in Enterobacterales and Pseudomonas aeruginosa.

Methods

Antimicrobial susceptibility of isolates collected from ATLAS (2017–2019) was determined per CLSI guidelines. Enterobacterales exhibiting meropenem MICs ≥2 mg/L and/or ceftazidime/avibactam and/or aztreonam/avibactam MICs ≥16 mg/L, Escherichia coli and Klebsiella pneumoniae with aztreonam and/or ceftazidime MICs ≥2 mg/L, and P. aeruginosa with meropenem MICs ≥4 mg/L were screened for β-lactamases by PCR and sequencing.

Results

Globally, ESBL-positive E. coli (23.7%, 4750/20047) and K. pneumoniae (35.1%, 6055/17229) carried predominantly the CTX-M-15 variant (E. coli: 53.9%; K. pneumoniae: 80.0%) with highest incidence in Africa/Middle East (AfME). Among carbapenem-resistant (CR) E. coli (1.1%, 217/20047) and Enterobacter cloacae (3.8%, 259/6866), NDMs were predominant (E. coli in AfME: 62.5%; E. cloacae in Asia Pacific: 59.7%). CR K. pneumoniae (13.3%, 2299/17 229) and P. aeruginosa (20.3%, 4187/20 643) carried predominantly KPC (30.9%) and VIM (14.7%), respectively, with highest frequency in Latin America. Among ESBL-positive Enterobacterales, susceptibility to ceftazidime/avibactam (>90.0%) and amikacin (>85.0%) was higher than to piperacillin/tazobactam (>45.0%) and ciprofloxacin (>7.4%). In CR Enterobacterales, susceptibility to amikacin (>54.0%) and ceftazidime/avibactam (>31.0%) was higher than to ciprofloxacin (>2.7%) and piperacillin/tazobactam (>0.5%). CR P. aeruginosa similarly demonstrated higher susceptibility to amikacin (63.4%) and ceftazidime/avibactam (61.9%) than to ciprofloxacin (26.2%) and piperacillin/tazobactam (25.3%).

Conclusions

Varied distribution of resistance genotypes across regions among ESBL-positive Enterobacterales and CR Enterobacterales and P. aeruginosa provide crucial insights on major resistance mechanisms and trends observed in recent years. Continued surveillance is warranted for monitoring global dissemination and resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimePseudomonas aeruginosaAnti-Bacterial AgentsAmikacinAztreonamMeropenemEscherichia coliIncidenceAzabicyclo Compoundsbeta-LactamasesPiperacillin, Tazobactam Drug CombinationKlebsiella pneumoniaeDrug CombinationsCiprofloxacinMicrobial Sensitivity TestsBacterial Proteins

Substanzen

CeftazidimeAnti-Bacterial AgentsAmikacinAztreonamMeropenemAzabicyclo Compoundsbeta-LactamasesPiperacillin, Tazobactam Drug CombinationDrug CombinationsCiprofloxacin

Autor:innen und Institutionen

  • Universidade Federal de São Paulo - UNIFESP, Division of Infectious Diseases, Department of Internal Medicine, Escola Paulista de Medicina - EPM, São Paulo - SP, Brazil.
  • Pfizer Inc., Groton, CT, USA.
  • International Health Management Associates, Inc., Schaumburg, IL, USA.

ORCID-Profile: Eric Utt

Förderung

  • Pfizer

Zitieren

APA

Gales, A. C., Stone, G., Sahm, D. F., Wise, M. G., & Utt, E. (2023). Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017–2019. Journal of Antimicrobial Chemotherapy, 78(7), 1606-1615. https://doi.org/10.1093/jac/dkad127

Vancouver

Gales AC, Stone G, Sahm DF, Wise MG, Utt E. Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017–2019. Journal of Antimicrobial Chemotherapy. 2023;78(7):1606-1615. doi:10.1093/jac/dkad127

BibTeX
@article{Gales2023,
  author = {Gales, Ana C and Stone, Gregory and Sahm, Daniel F and Wise, Mark G and Utt, Eric},
  title = {Incidence of ESBLs and carbapenemases among Enterobacterales and carbapenemases in Pseudomonas aeruginosa isolates collected globally: results from ATLAS 2017–2019},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  volume = {78},
  number = {7},
  pages = {1606--1615},
  doi = {10.1093/jac/dkad127}
}
Kostenlos starten →